跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ODEFSEY - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ODEFSEY
Authorized
STANDARD
ODEFSEY
gilead sciences canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
a880930e887a5cb9
Company
gilead sciences canada inc
Type
Standard
Approval Details
Approval Id
a880930e887a5cb9
Drug Approval Canada Name
ODEFSEY
Product Name
ODEFSEY
Status
Marketed
Status Date
2017-03-20
Original Market Date
2017-03-20
Din
02461463
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.16
Atc Original
J05AR19 EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND RILPIVIRINE
Atc Name
j 05 ar 19
Aig Number
0358830001
Company Name
gilead sciences canada inc
Company Address
400, 6925 Century Avenue, Mississauga, Ontario, Canada, L5N 7K2
Active Ingredients
EMTRICITABINE
200 MG
TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
25 MG
RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE)
25 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
a880930e887a5cb9
Type
Standard
Back to Health Canada Approvals